These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36750457)

  • 21. Effectiveness and safety of dupilumab in adults with moderate and severe atopic dermatitis in Colombia: Real-life experience.
    Londoño J; Perez L; Moreno S; Chapman E; Garcia MB; Celis AM; Muñoz MA; Castillo D; Sánchez J; Arevalo Y; Lozano A; Alvis-Zakzuk NJ; Muñoz C; Botero L; Beltran C; García E
    World Allergy Organ J; 2023 Apr; 16(4):100763. PubMed ID: 37091550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dupilumab shows slow, steady effectiveness for intractable prurigo in patients with atopic dermatitis.
    Takeuchi S; Inoue K; Kuretake K; Kiyomatsu-Oda M; Furue M
    J Dermatol; 2021 May; 48(5):638-644. PubMed ID: 33742710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.
    O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R
    Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The ability of biomarkers to assess the severity of atopic dermatitis.
    Nakahara T; Onozuka D; Nunomura S; Saeki H; Takenaka M; Matsumoto M; Kataoka Y; Fujimoto R; Kaneko S; Morita E; Tanaka A; Saito R; Okano T; Miyagaki T; Aoki N; Nakajima K; Ichiyama S; Kido-Nakahara M; Tonomura K; Nakagawa Y; Tamagawa-Mineoka R; Masuda K; Takeichi T; Akiyama M; Ishiuji Y; Katsuta M; Kinoshita Y; Tateishi C; Yamamoto A; Morita A; Matsuda-Hirose H; Hatano Y; Kawasaki H; Fukushima-Nomura A; Ohtsuki M; Kamiya K; Kabata Y; Abe R; Mitsui H; Kawamura T; Tsuji G; Katoh N; Furue M; Izuhara K
    J Allergy Clin Immunol Glob; 2024 Feb; 3(1):100175. PubMed ID: 37915726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy.
    Stingeni L; Hansel K; Antonelli E; Bello GD; Patruno C; Napolitano M; Fabbrocini G; Grieco T; Pellacani G; Fargnoli MC; Esposito M; Piras V; Zucca M; Girolomoni G
    Dermatol Ther; 2021 Sep; 34(5):e15035. PubMed ID: 34152670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.
    Yosipovitch G; de Bruin-Weller M; Armstrong A; Wu JJ; Herranz P; Thaçi D; Delevry D; Bagousse GB; Zhang R; Shumel B; Rossi AB; Chao J
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):2147-2157. PubMed ID: 34714527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
    Fargnoli MC; Esposito M; Ferrucci S; Girolomoni G; Offidani A; Patrizi A; Peris K; Costanzo A; Malara G; Pellacani G; Romanelli M; Amerio P; Cristaudo A; Flori ML; Motolese A; Betto P; Patruno C; Pigatto P; Sirna R; Stinco G; Zalaudek I; Bianchi L; Boccaletti V; Cannavò SP; Cusano F; Lembo S; Mozzillo R; Gallo R; Potenza C; Rongioletti F; Tiberio R; Grieco T; Micali G; Persechino S; Pettinato M; Pucci S; Savi E; Stingeni L; Romano A; Argenziano G;
    J Dermatolog Treat; 2021 Aug; 32(5):507-513. PubMed ID: 31647347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
    Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
    JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset.
    Eichenfield LF; Armstrong A; Guttman-Yassky E; Lio PA; Chen CC; Hines DM; McGuiness CB; Ganguli S; Delevry D; Sierka D; Mallya UG
    Dermatol Ther (Heidelb); 2022 Jun; 12(6):1337-1350. PubMed ID: 35543920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.
    Wang FP; Tang XJ; Wei CQ; Xu LR; Mao H; Luo FM
    J Dermatol Sci; 2018 May; 90(2):190-198. PubMed ID: 29472119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients.
    Barei F; Zussino M; Tavecchio S; Angileri L; Rizzo A; Calzari P; Marzano AV; Ferrucci S
    Pharmaceuticals (Basel); 2024 Jan; 17(1):. PubMed ID: 38256950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials.
    Alexis AF; Rendon M; Silverberg JI; Pariser DM; Lockshin B; Griffiths CE; Weisman J; Wollenberg A; Chen Z; Davis JD; Li M; Eckert L; Gadkari A; Shumel B; Rossi AB; Graham NM; Ardeleanu M
    J Drugs Dermatol; 2019 Aug; 18(8):804-813. PubMed ID: 31424712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal course and phenotypes of health-related quality of life in adults with atopic dermatitis.
    Schwartzman G; Lei D; Ahmed A; Chavda R; Gabriel S; Silverberg JI
    Clin Exp Dermatol; 2022 Feb; 47(2):359-372. PubMed ID: 34623642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.
    Reich K; Lio PA; Bissonnette R; Alexis AF; Lebwohl MG; Pink AE; Kabashima K; Boguniewicz M; Nowicki RJ; Valdez H; Zhang F; DiBonaventura M; Cameron MC; Clibborn C
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3228-3237.e2. PubMed ID: 36108923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Paller AS; Simpson EL; Siegfried EC; Cork MJ; Wollenberg A; Arkwright PD; Soong W; Gonzalez ME; Schneider LC; Sidbury R; Lockshin B; Meltzer S; Wang Z; Mannent LP; Amin N; Sun Y; Laws E; Akinlade B; Dillon M; Kosloski MP; Kamal MA; Dubost-Brama A; Patel N; Weinreich DM; Yancopoulos GD; O'Malley JT; Bansal A;
    Lancet; 2022 Sep; 400(10356):908-919. PubMed ID: 36116481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
    Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
    BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19-Associated Disease Course Is Shortened in Moderate-to-Severe Atopic Dermatitis Patients Receiving Dupilumab Treatment: A Retrospective Cross-Sectional Study.
    Ma D; Wang Y; Huang N; Li W; Chen H; Yang Y; Zhu R
    J Clin Med; 2023 May; 12(10):. PubMed ID: 37240520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study.
    Zhou B; Peng C; Li L; Liu R; Zhu L; Chen X; Li J
    Front Med (Lausanne); 2022; 9():838030. PubMed ID: 35402441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.